论文部分内容阅读
目的:探讨羟考酮缓释片在鼻咽癌同步放化疗期间放射性口咽粘膜反应治疗中的临床应用价值。方法:从我院2015年12月-2016年12月选取46例鼻咽癌放疗患者参与试验,并随机划分为两组(23例/组),Ⅰ组接受自配口腔含漱液止痛治疗,Ⅱ组接受自配口腔含漱液加羟考酮缓释片止痛治疗,评估该两种止痛治疗方法的临床实施情况。结果:Ⅱ组总疼痛缓解率为95.7%,控制达到轻度及以下疼痛为43.5%,相比Ⅰ组的65.2%与13.0%均明显提高,P<0.05,差异有统计学意义。Ⅱ组总不良反应率为43.48%,以便秘及恶心呕吐常见,相比Ⅰ组的总不良反应率(13.04%)显著提高,P<0.05,差异有统计学意义。结论:鼻咽癌同步放化疗3-4级放射性口咽粘膜反应,应用羟考酮缓释片+口腔含漱液可有效缓解患者疼痛,便秘、恶性、呕吐等副反应常见,在可控可处理范围内,适合推广应用于临床。
Objective: To investigate the clinical value of oxycodone sustained-release tablets in the treatment of radioactive oropharyngeal mucosa during concurrent chemoradiotherapy of nasopharyngeal carcinoma. Methods: From December 2015 to December 2016, 46 patients with radiotherapy of nasopharyngeal carcinoma were enrolled in the study. Patients were randomly divided into two groups (23 patients / group). Patients in group I received oral gargle solution for pain relief. Group Ⅱ received self-made oral gargle plus oxycodone sustained-release tablets analgesic treatment to evaluate the clinical implementation of the two pain-relieving treatment methods. Results: The total pain relief rate in group Ⅱ was 95.7%, and the control pain was mild and below 43.5%, which was significantly higher than 65.2% and 13.0% in group Ⅰ (P <0.05). The difference was statistically significant. In group Ⅱ, the total adverse reaction rate was 43.48%. Constipation and nausea and vomiting were common. The total adverse reaction rate (13.04%) in group Ⅱ was significantly higher than that in group Ⅰ (P <0.05). The difference was statistically significant. CONCLUSIONS: Grade 3-4 radioactive oropharyngeal mucosa reaction of nasopharyngeal carcinoma with concurrent chemoradiation and chemotherapy, oxycodone extended-release tablets and oral rinse solution can effectively relieve the pain, constipation, malignant, vomiting and other side effects in patients with common, Within the scope of treatment, suitable for the promotion of clinical application.